transplant rejection

22
TRANSPLANT REJECTION BALAJI.R ALTHEANZ 09’

Upload: srinivasan-gunasekaran

Post on 24-May-2015

564 views

Category:

Health & Medicine


3 download

TRANSCRIPT

Page 1: Transplant rejection

TRANSPLANT REJECTION

BALAJI.RALTHEANZ 09’

Page 2: Transplant rejection

Rejection is a complex process in which “recepient immune system recognize the graft as foreign and attacks it”.

It involves 1. Cell mediated immunity 2. Circulating antibodies

REJECTION

Page 3: Transplant rejection

It is caused by T-cell mediated reactions. Destruction of grafts occurs by 1. CD8+ CTLs 2. CD4+ helper cells Delayed hypersensitivity is triggered by

CD4+ helper cells. 2 pathways 1. Direct pathway 2. Indirect pathway

CELLULAR REJECTION

Page 4: Transplant rejection
Page 5: Transplant rejection

It is called humoral rejections. 2 types 1. Hyperacute

2. Acute

HYPERACUTE: Presence of preformed antidonor

antibodies. Transplant rejection has already occurred.

ANTIBODY MEDIATED REACTIONS

Page 6: Transplant rejection

ACUTE: Initial exposure to class I&II HLA

antigens. Antibodies causes injury by 1. Complement dependent

cytotoxicity 2. Inflammation 3. Antibody dependent cell

mediated cytotoxicity.

Page 7: Transplant rejection

Rejection reactions 1. Hyperacute 2. Acute a. cellular b. humoral 3. Chronic

MORPHOLOGY

Page 8: Transplant rejection

Occurs within minutes or hours after transplantation.

Kidney becomes 1. Cyanotic 2. Mottled 3. Flaccid Immunoglobulin and complement

deposition occurs. Neutrophils accumulate leading to occlusion

of capillaries & fibrinoid necrosis.

HYPERACUTE

Page 9: Transplant rejection
Page 10: Transplant rejection

Cellular – mononuclear cell infiltrate Humoral – vasculitis ACUTE CELLULAR: Seen within initial months after

transplantation. Mononuclear cells accumulates in

glomerular and peritubular capillaries leading to FOCAL TUBULAR NECROSIS.

Treatment – cyclosporin.

ACUTE

Page 11: Transplant rejection
Page 12: Transplant rejection

Also known as rejection vasculitis. Necrotizing vasculitis characterised by

intimal thickening. Presence of complement breakdown

product C4d – indicator of humoral rejection.

Treatment – B cell depleting agents.

ACUTE HUMORAL REJECTION

Page 13: Transplant rejection
Page 14: Transplant rejection

CHRONIC REJECTION

Page 15: Transplant rejection

GRAFT ATERIOSCLEROSIS

Page 16: Transplant rejection

Immunosuppressive agents 1. Cyclosporin 2. Azathioprine 3. Steroids 4. Rapamycin 5. Monoclonal antibodies.

METHODS OF INCREASING GRAFT SURVIVAL

Page 17: Transplant rejection

ANOTHER METHOD: Prevention of host T cells from

receiving co-stimulatory signals (B7-1&2) from dendritic cells.

DISADVANTAGES: EBV induced lymphoma HPV induced squamous cell carcinoma Kaposi sarcoma

Page 18: Transplant rejection

Hematopoietic stem cell transplants are used for

1. Hematological malignancy 2. Aplastic anemia 3. Thalassemia 4. Non hematological cancersPROBLEMS: 1. Immunodeficiency 2. GVH disease

HEMATOPOIETIC STEMCELLS

Page 19: Transplant rejection

Occurs in any situation in which “immunologically competent cells or their precursors are transplanted to immunologically crippled recipients and the transferred cells recognize allo-antigens in the host”.

It may be 1. Acute 2. Chronic

GRAFT VS HOST DISEASE

Page 20: Transplant rejection

Days to weeks after allogenic bonemarrow transplantation.

Clinical features 1. Generalised rash 2. Jaundice 3. Ulceration of gut 4. Bloody diarrhea

ACUTE GVH

Page 21: Transplant rejection

Follow acute syndrome or occur insidiously.

Clinical features 1. Cutaneous injury 2. Cholestatic jaundice 3. Esophageal strictures 4. Depletion of lymphocytes It is a life threatning condition. Treatment – bonemarrow transplants.

CHRONIC GVH

Page 22: Transplant rejection

THANK YOU